Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE               Parliamentary submission
DATE                 2014-10-28
TOPICS          Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE    Parliamentary submission
DATE            2015-05-14
TOPICS          Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE  Parliamentary submission
DATE  2014-06-11
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE  Parliamentary submission
DATE  2018-04-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE  2017-05-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

POLICY TYPE: Parliamentary submission
DATE: 2014-05-15
TOPICS: Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Cannabis for Medical Purposes

CMA POLICY

CANNABIS policy

The Canadian Medical Association (CMA) has always been supportive of measures that balance public health with individual rights. We believe that cannabis should be regulated as a controlled substance, and that the current regulatory framework should be reviewed to ensure that it is evidence-based and meets public health needs.

We understand that cannabis may have therapeutic benefits for certain medical conditions. However, the evidence supporting these benefits is not yet conclusive. Therefore, we support ongoing research to better understand the therapeutic effects of cannabis.

Below are some of our key recommendations:

1. **Regulation and Licensing:** We support the development of a robust regulatory framework that ensures public safety and health. The framework should include stringent licencing requirements for producers, distributors, and retailers. It should also mandate robust quality control and testing protocols.

2. **Research and Education:** We encourage ongoing research to better understand the therapeutic effects of cannabis. This research should include safety, efficacy, and potential risks associated with its use. We also recommend targeted education programs for healthcare professionals, patients, and the general public.

3. **Access to Care:** We support the provision of cannabis in a manner that is accessible to those who have a medical need. This includes ensuring that patients have access to qualified healthcare providers who can assess their medical needs and prescribe cannabis when appropriate.

4. **Public Health:** We emphasize the importance of public health in the regulation of cannabis. Measures should be in place to prevent misuse, address public health concerns, and support addiction treatment programs.

The CMA will continue to monitor developments in this area and will provide updates as more information becomes available.
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal

https://policybase.cma.ca/link/policy10702

POLICY TYPE  Parliamentary submission
DATE       2013-02-28
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE: Response to consultation
DATE: 2017-06-28
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13641

POLICY TYPE  Parliamentary submission
DATE  2017-04-07
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE: Parliamentary submission
DATE: 2018-02-15
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE       Response to consultation
DATE             2015-06-08
TOPICS           Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA's Submission to the House of Commons Standing Committee on Health: CMA Policybase - Canadian Medical Association
CMA’s Submission to the House of Commons Standing Committee on Health: Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE Parliamentary submission
DATE 2012-03-29
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE  Parliamentary submission
DATE  2014-03-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE
Parliamentary submission

DATE
2012-10-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE                  Parliamentary submission
DATE                        2017-04-06
TOPICS                      Pharmaceuticals, prescribing, cannabis, drugs

Documents
Complementary and alternative medicine (update 2015)
https://policybase.cma.ca/link/policy11529

POLICY TYPE
Policy document

DATE
2015-05-30

REPLACES
Complementary and alternative medicine (Update 2008)

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents